Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boryung
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Korea
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Duodenal Ulcer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BR-ARC-CT-103 | P1 |
Completed |
Duodenal Ulcer |
2023-09-12 |
21% |
BR-ARC-CT-102 | P1 |
Completed |
Duodenal Ulcer |
2023-08-24 |
21% |